Perez D J, Powles T J, Gazet J C, Ford H T, Coombes R C
Cancer Chemother Pharmacol. 1984;13(1):36-8. doi: 10.1007/BF00401444.
Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen. Of 48 evaluable patients 19 (40%) responded for a median period of 5 months and 12 (25%) had stabilisation of disease. Of the 12 patients previously treated with adriamycin only one responded, whereas 18 of the 36 patients without previous chemotherapy responded. Although healing of bone metastases was infrequent control of hypercalcaemia was commonly seen. Generally the treatment was well tolerated and treatment was stopped in only five patients because of toxicity. Cumulative marrow toxicity was observed but was not a significant problem in the first 6 months of treatment. Mitomycin C, melphalan, and methotrexate (MMM) appears to provide an effective, well tolerated chemotherapy combination for metastatic breast carcinoma.
57例转移性乳腺癌患者接受了丝裂霉素C（10mg/m²静脉注射，每6周1次）、美法仑（6mg/m²口服，连用3天，每3周1次）和甲氨蝶呤（35mg/m²静脉注射，每3周1次）治疗，以评估该方案的疗效和毒性。48例可评估患者中，19例（40%）有反应，中位反应期为5个月，12例（25%）病情稳定。在12例既往仅接受过阿霉素治疗的患者中，只有1例有反应，而在36例既往未接受过化疗的患者中，18例有反应。虽然骨转移很少愈合，但高钙血症通常得到控制。总体而言，该治疗耐受性良好，仅5例患者因毒性而停止治疗。观察到有累积性骨髓毒性，但在治疗的前6个月这不是一个严重问题。丝裂霉素C、美法仑和甲氨蝶呤（MMM）似乎为转移性乳腺癌提供了一种有效且耐受性良好的化疗组合。
